The expansion of a polyglutamine tract in the ataxin-1 protein beyond a critical threshold causes spinocerebellar ataxia type 1 (SCA1). To investigate the mechanism of neuronal degeneration in SCA1, we analyzed the phenotype of an SCA1 transgenic mouse model in the absence of p53, an important regulator of cell death. p53 deficiency did not affect the early features of SCA1 mice such as impaired motor coordination and ataxin-1 nuclear inclusion formation but caused a notable reduction in later pathological features, including Purkinje cell heterotopia, dendritic thinning, and molecular layer shrinkage. To determine if this protective effect was mediated by an anti-apoptotic property of p53 deficiency, we looked for apoptosis in SCA1 mice but failed to detect any evidence of it even in the presence of p53. We propose that p53 acts after the initial pathogenic events in SCA1 to promote the progression of neuronal degeneration in SCA1 mice, but this activity may be unrelated to apoptosis.
INTRODUCTION
Spinocerebellar ataxia type 1 (SCA1) is one of several neurodegenerative diseases caused by the expansion of a CAG trinucleotide repeat beyond a critical threshold, resulting in a protein with an expanded polyglutamine tract (Zoghbi and Orr, 2000) . SCA1, with a typical onset in the 20s or 30s, is characterized by progressively worsening gait ataxia, speech and swallowing difficulties, involuntary eye movements, and muscle atrophy (Zoghbi and Orr, 1995) . Associated with these phenotypic defects is a profound loss of cerebellar Purkinje cells and brainstem neurons (Zoghbi and Orr, 1995) . Transgenic mice harboring the human SCA1 coding sequence with 82 CAG repeats under the control of the Purkinje cell protein-2 (Pcp2) promoter develop a progressive neurodegenerative phenotype (Burright et al., 1995) . Impaired motor performance as measured by the accelerating rotating rod apparatus appears early, around 5 weeks of age. At 6 weeks, the mutant ataxin-1 protein is found in aggregates within Purkinje cell nuclei, with the number of cells containing aggregates increasing over time. This is accompanied by other changes such as decreases in the number of Purkinje cell proximal branches and dendritic spines. When the mice reach 12 weeks of age, their gait is overtly ataxic. By 15 weeks, Purkinje cells exhibit profound changes, including substantially reduced dendritic arborization, displacement from the Purkinje cell layer into the molecular layer (heterotopia), and shrinkage of the molecular layer. Purkinje cell loss is mild at 12 weeks of age, but becomes significant at 24 weeks of age, with an approximate 30% reduction in the Purkinje cell population (Clark et al., 1997) .
Loss of specific neurons is characteristic of the polyglutamine diseases, and because of the importance of apoptosis in regulating responses to cellular damage, it has been hypothesized that polyglutamine proteins may activate the apoptotic machinery and that this cell loss may be a central component of the disease (Paulson et al., 2000) , but this idea is controversial. Various results have suggested that neuronal death in polyglutamine diseases may not be apoptotic. For example, neuronal degeneration in a Huntington disease (HD) Drosophila model is not rescued by expression of the anti-apoptotic viral P35 protein, indicating that apo-
